^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PI3Kγ inhibitor

    Related drugs:
    Apply
    Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma (A051902) (NCT04803201)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    10/08/2021
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME
    |
    TNFRSF8 expression
    |
    doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous
    A Study of Ruxolitinib and Duvelisib in People With Lymphoma (NCT05010005)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    08/12/2021
    Primary completion :
    08/01/2026
    Completion :
    08/01/2026
    CD8
    |
    CD8 positive
    |
    Jakafi (ruxolitinib) • Copiktra (duvelisib)
    Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy (NCT05065866)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/18/2021
    Primary completion :
    01/02/2024
    Completion :
    06/01/2025
    ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Copiktra (duvelisib) • Onureg (azacitidine oral)
    Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study (NCT04890236)
    Phase 1
    Emory University
    Completed
    Last update posted :
    01/20/2025
    Initiation :
    01/13/2022
    Primary completion :
    03/20/2024
    Completion :
    09/04/2024
    CD27
    |
    Copiktra (duvelisib) • Kymriah (tisagenlecleucel-T) • ETP-47187
    Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma (NCT04688658)
    Phase 1/2
    John Kirkwood
    Active, not recruiting
    Last update posted :
    08/08/2024
    Initiation :
    07/21/2021
    Primary completion :
    02/22/2024
    Completion :
    12/01/2028
    BRAF • CD8
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • Inlyta (axitinib) • Copiktra (duvelisib)
    Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03961672)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/15/2024
    Initiation :
    05/13/2020
    Primary completion :
    06/27/2024
    Completion :
    06/27/2024
    BCL2 • CCND1 • FCER2
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Copiktra (duvelisib) • ETP-47187
    Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS (NCT03534323)
    Phase 1/2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    01/09/2024
    Initiation :
    07/12/2018
    Primary completion :
    07/01/2024
    Completion :
    07/01/2026
    BCL2
    |
    Venclexta (venetoclax) • Copiktra (duvelisib)
    Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC (NCT05057247)
    Phase 2
    Glenn J. Hanna
    Active, not recruiting
    Last update posted :
    12/07/2023
    Initiation :
    10/14/2021
    Primary completion :
    10/01/2023
    Completion :
    01/01/2025
    PD-L1
    |
    PD-L1 expression
    |
    docetaxel • Copiktra (duvelisib)
    Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (NCT03961698)
    Phase 2
    Infinity Pharmaceuticals, Inc.
    Active, not recruiting
    Last update posted :
    08/10/2023
    Initiation :
    12/17/2019
    Primary completion :
    08/31/2023
    Completion :
    08/31/2023
    HER-2 • PD-L1 • ER • PGR
    |
    PD-L1 expression • HER-2 negative
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • albumin-bound paclitaxel • eganelisib (IPI-549)
    Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL (NCT05239910)
    Phase 2
    Rhizen Pharmaceuticals SA
    Withdrawn
    Last update posted :
    10/17/2022
    Initiation :
    01/01/2023
    Primary completion :
    12/01/2026
    Completion :
    05/01/2027
    ALK • TNFRSF8
    |
    ALK positive
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • tenalisib (RP6530)
    A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 (NCT02637531)
    Phase 1
    Infinity Pharmaceuticals, Inc.
    Active, not recruiting
    Last update posted :
    04/04/2022
    Initiation :
    12/01/2015
    Primary completion :
    01/01/2022
    Completion :
    12/01/2022
    HER-2 • ER • ALK • PGR • MSI
    |
    MSI-H/dMMR • ER negative • PGR negative
    |
    Opdivo (nivolumab) • eganelisib (IPI-549)
    Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies (SCRI HEMREF 34) (NCT01871675)
    Phase 1
    SCRI Development Innovations, LLC
    Completed
    Last update posted :
    07/11/2016
    Initiation :
    05/01/2013
    Primary completion :
    06/01/2016
    Completion :
    06/01/2016
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • Copiktra (duvelisib) • bendamustine